Isatuximab

12:03
How will novel agents affect the amyloidosis population?
Morie Gertz et al.
13:14
Amyloidosis: diagnosis and stem cell transplantation
Morie Gertz et al.
1:11
Attacking plasma cell dyscrasia in AL amyloidosis
Vaishali Sanchorawala
10:42
Highlights from IMW 2019 Part I
Francesca Gay et al.
1:55
Katja Weisel: GMMG-CONCEPT
Katja Weisel
5:22
Updates on German clinical trials in multiple myeloma
Marc Raab
7:37
Prevention and management of adverse events in relapsed myeloma
Michel Delforge
3:30
Isatuximab: an important new option in R/R MM
Paul Richardson
1:24
Multiple myeloma treatment strategies: what does the future hold?
Enrique Ocio
2:24
Drug trial updates in multiple myeloma and SMM
Enrique Ocio
5:22
ICARIA study: Isatuximab and pom/dex for multiple myeloma
Paul Richardson
3:23
Upcoming updates in multiple myeloma
Thierry Facon
6:09
Induction in myeloma: a journey over time
Mohamad Mohty
3:11
Isatuximab plus VRd for newly diagnosed transplant-ineligible myeloma
Enrique Ocio
04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
1:46
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
Niels van de Donk
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals